OS Therapies Inc

OS Therapies’ FDA Type C meeting on OST‑HER2 marks a milestone in osteosarcoma treatment, highlighting clinical progress and investor interest amid market volatility.

OS Therapies Incorporated, a clinical-stage biopharmaceutical company, is making significant strides in the oncology sector by developing innovative treatments for osteosarcoma and other solid tumors.

OS Therapies Inc. announces landmark 2-year overall survival results for its lead candidate, OST-HER2, in a Phase 2b study of metastatic osteosarcoma, with a statistically significant improvement over historical controls, and receives positive regul…

OS Therapies Inc, a biopharmaceutical company focused on treating osteosarcoma and solid tumors, faces significant financial challenges, including a negative price-to-earnings ratio and volatile stock price, which threaten its ability to continue it…

OS Therapies Inc, a biopharmaceutical company focused on treating osteosarcoma and other solid tumors, faces significant financial challenges and uncertainty, raising questions about its viability and future prospects.

OS Therapies Inc is a clinical-stage biopharmaceutical company dedicated to developing treatments for osteosarcoma and other solid tumors, offering a beacon of hope in the fight against cancer.

OS Therapies Inc has completed a significant acquisition of Advaxis Immunotherapies’ assets, marking a pivotal moment in its strategic expansion and potentially solidifying its position in the fight against osteosarcoma and other solid tumors.